作者: Neeltje van Doremalen , Vincent J. Munster
DOI: 10.1016/J.ANTIVIRAL.2015.07.005
关键词:
摘要: The emergence of the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 marked second time that a new, highly pathogenic has emerged human population 21st century. In this review, we discuss current state knowledge animal models MERS-CoV infection. Commonly used laboratory species such as Syrian hamsters, mice and ferrets are not susceptible to MERS-CoV, due differences receptor dipeptidyl peptidase 4 (DPP4). initially developed comprise two nonhuman primate species, rhesus macaque common marmoset. Rhesus macaques develop mild moderate disease upon inoculation, reminiscent milder MERS cases, whereas marmosets severe disease, recapitulating observed some patients. Dromedary camels, considered be reservoir for upper tract infection with abundant viral shedding. Although normal expression DPP4 (hDPP4) overcomes lack susceptibility. Transgenic hDPP4 lethal inoculation MERS-CoV. These transgenic potentially ideal first line model efficacy testing therapeutic prophylactic countermeasures. Further characterization identified countermeasures would ideally performed marmoset model, more outcome. This article forms part symposium Antiviral Research on "From SARS MERS: research coronaviruses."